Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
MWN-AI** Summary
Harbour BioMed, a global biopharmaceutical firm specializing in novel antibody therapeutics, has announced a significant strategic move by acquiring common stock in Spruce Biosciences, Inc. Through its subsidiary, Harbour BioMed has exercised its warrant, resulting in ownership of approximately 3.8% of Spruce's total outstanding shares and about 3.1% of fully diluted shares. This acquisition marks a crucial advancement in the partnership between the two companies, evolving from a standard licensor-licensee relationship into a more strategically aligned collaboration.
The warrant exercised by Harbour BioMed was initially granted as part of a license and collaboration agreement between its subsidiary, HBM Alpha Therapeutics (HBMAT), and Spruce. The collaboration focuses on the development of SPR202, a monoclonal antibody aimed at treating disorders such as congenital adrenal hyperplasia. Harbour BioMed's CEO, Dr. Jingsong Wang, emphasized that this milestone enhances their commitment to jointly accelerate the development of innovative therapies that can significantly improve patient outcomes globally.
Harbour BioMed is recognized for its pioneering antibody technology, particularly through its proprietary Harbour Mice® platform, which enables the generation of fully human monoclonal antibodies. This platform supports the company's efforts to build a robust pipeline of therapeutics in immunology and oncology, capitalizing on strategic partnerships and selective acquisitions to advance its development capabilities.
Overall, this acquisition of common stock in Spruce Biosciences deepens Harbour BioMed's strategic collaboration, providing a stronger foundation for the joint advancement of potentially transformative therapies that target high unmet medical needs.
MWN-AI** Analysis
Harbour BioMed’s recent acquisition of common stock in Spruce Biosciences highlights a strategic pivot that investors should closely monitor. By increasing its stake to approximately 3.8% of Spruce's outstanding shares, Harbour BioMed not only solidifies its financial investment but also deepens its collaborative framework aimed at advancing innovative therapies.
From a market perspective, this acquisition can signal heightened confidence in Spruce Biosciences' pipeline, particularly concerning SPR202, an anti-corticotropin-releasing hormone monoclonal antibody intended for significant medical conditions. As Harbour BioMed transitions from a traditional licensee relationship to a strategic partnership with Spruce, it boosts the prospects of co-development, potentially leading to faster go-to-market timelines for breakthrough therapies.
For investors, this move could represent an opportunity, particularly given Harbour BioMed's commitment to developing transformative treatments in immunology and oncology. The robust pipeline supported by proprietary technology platforms like Harbour Mice® and its advanced bispecific antibody technologies may enhance the overall market value of both companies. As such, investing in Harbour BioMed might offer substantial growth potential, especially as new data on SPR202 emerges.
Additionally, it's wise to keep an eye on the broader biopharmaceutical market trends, especially with increasing scrutiny on drug development timelines and regulatory approvals which could impact stock valuations in the sector.
In conclusion, Harbour BioMed's strategic acquisition of Spruce's stock is a positive indicator, suggesting potential growth in both entities. Investors looking for exposure in the biopharmaceutical sector may find Harbour BioMed an attractive option, especially as developments unfold in its collaborative endeavors. As always, thorough due diligence remains crucial.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].
The warrant was originally issued to Harbour BioMed's subsidiary and other minority shareholders of HBM Alpha Therapeutics ("HBMAT"), an innovative biotechnology company incubated by Harbour BioMed, in connection with a license and collaboration agreement by and between HBMAT and Spruce. The collaboration aims to advance the development of SPR202 (formerly known as HBM9013 by Harbour BioMed), a potent and selective anti-corticotropin-releasing hormone monoclonal antibody for various disorders, including congenital adrenal hyperplasia.
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, stated: "This warrant exercise marks a significant milestone in our relationship with Spruce Biosciences. It moves us beyond a traditional licensor-licensee relationship to a truly aligned strategic partnership, reinforcing our shared commitment to accelerating the development of transformative therapies for patients worldwide."
[1] Calculated based on the total outstanding shares and fully diluted shares of Spruce as of September 30, 2025. |
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.
SOURCE Harbour BioMed
FAQ**
How does Harbour BioMed's acquisition of common stock in Spruce Biosciences Inc. (SPRB) enhance its strategic collaboration in developing therapies for disorders like congenital adrenal hyperplasia?
What are the potential implications of Harbour BioMed holding approximately 3.8% of Spruce Biosciences Inc. (SPRB) for future collaborative projects between the two companies?
How might the exercise of this warrant by Harbour BioMed impact its overall financial position and future growth prospects, particularly in relation to Spruce Biosciences Inc. (SPRB)?
What specific advancements in the development of SPR202 are expected from the strengthened partnership between Harbour BioMed and Spruce Biosciences Inc. (SPRB) following this stock acquisition?
**MWN-AI FAQ is based on asking OpenAI questions about Spruce Biosciences Inc. (NASDAQ: SPRB).
NASDAQ: SPRB
SPRB Trading
-3.56% G/L:
$64.05 Last:
23,587 Volume:
$62.64 Open:
